We would love to hear your thoughts about our site and services, please take our survey here.
If you think it’s worth 50 p then wait for that entry point. In my opinion £1 will be seen as a bargain shortly. Your argument around earnings to date would be relevant if this were a supermarket but biotech on the cusp of a paradigm shift in Oncology probably won’t perform like a supermarket. deals get signed and further data adds to the case. Remember we have been told by several members of the board that the WHOLE platform has been validated. Others have already filled you in with what Ava6000 will, in Pharma terms, shortly be worth. Good luck on 50p entry point
Clearly wasn’t? Two early development specialists leave a company transitioning to clinical and business development stage. Clearly is to me. If it’s worrying you that much why don’t you sell up and leave us all to it? Oh I know, your not invested in the first place, and this is your excuse for some kind of weird social life.
There’s plenty of big Farmers round my way that probably could take Avacta out at the current price, but I’m unsure of their route to commercialisation. They’d probably end up feeding the affimers to the pigs.
If that’s your opinion Trendz, then maybe, rather than preaching to our delusional echo chamber, your time would be better spent selling your house , going on holiday, and coming back and buying two houses or even three come the 70p raise.
Talk us through Alastair Smiths commercial failures at Aviva Robin? Is it the Affimer platform currently in PD-L1 preclinical trials, the Affyxell collaboration in Korea, Ava3996’s IND application or the ongoing trial of Ava6000 in some of the most respected cancer hospitals in the US? Biotechs loose money until they hit the jackpot, few shots on goal there don’t you think?
You’re forgetting the CEO has already told us that the platform is validated. We all know you and Derek are trying to establish a ‘ P2 is when this moves’ narrative. I suspect to give your duster of another share time to mature. I’m just setting it straight that this could move any day on a deal landing for the validated platform. Like I’ve said before, leave us fools to it and see you during P2.
This looks to be the company William Bachovchin founded to move forward ava3996 and 6000. I presume he then realised the work needed to push them though all the preclinical and clinical work and decided to license it to Avacta.
No Derek my point is that many of the ADC deals going through for huge sums of money are for sales way in the future . 2026 is near term in the Pharma world. Listen to Novartis CEO talking yesterday, they plan over decades not weeks and months. Get it?
Https://www.fiercebiotech.com/biotech/jpm24-lilly-ceo-david-ricks-biotechs-were-open-business
This article suggests slightly different. For a platform or pipeline, price tag isn’t an issue
Donkey, I’d have thought they might have signed an agreement not to talk to media during the trial or their ongoing treatment, I’m sure they wouldn’t want to jeopardise their on going Chemo by doing so. It’ll come, it’s just a matter of patience and enrolling more patients
Exactly Ice, patients in C4 and 5 that continue to have stable disease or tumour shrinkage will now be going way past where their life expectancy would have been on dox. C6 and c7 will be heading that way, with hope